in nasopharyngeal swabs obtained upon admission. All of the patients were treated with oral clarithromycin (15 mg/kg/day in two doses). Comparison was made between children with macrolide-resistant M. pneumoniae and those with macrolide-sensitive M. pneumoniae. The continuous variables were analyzed using a two-sided Student test if they were normally distributed (on the basis of the Shapiro-Wilk statistic), or a two-sided Wilcoxon rank-sum test if they were not. The categorical variables were analyzed using contingency table analysis and the chi-squared or Fisher's test, as appropriate. All of the analyses were two-tailed, and P values of Յ0.05 were considered significant. Table 1 summarizes the demographic, clinical, laboratory, and radiographic findings and outcomes in the macrolide-resistant and macrolide-sensitive patients. The data show that the presence of macrolide-resistant M. pneumoniae does not change the presentation of CAP, because the signs and symptoms, laboratory results, and radiographic findings were similar in the two groups, regardless of the M. pneumoniae sensitivity to the macrolides. However, despite macrolide administration, the duration of fever and cough was significantly longer in the children with macrolideresistant M. pneumoniae infection, as was the duration of hospitalization and antibiotic administration. Moreover, in seven of the eight patients with macrolide-resistant M. pneumoniae infection (87.5%), the persistence of symptoms led to clarithromycin being replaced by levofloxacin, which was followed by the prompt resolution of fever and cough.
These data seem to make a further contribution to the debate concerning the importance of treating M. pneumoniae infection with antibiotics and the clinical relevance of macrolide resistance. In CAP cases due to sensitive strains, macrolides appear useful because they reduce the duration of symptoms, although it is not clear whether their activity is due mainly to their antimicrobial or anti-inflammatory properties. However, the clinical relevance of macrolide resistance in hospitalized CAP patients seems to be limited to prolonging the symptoms of the disease and not to increasing the risk of complications. Another antibiotic, such as a fluoroquinolone, should be prescribed if the symptoms persist or if there are signs of clinical deterioration. However, before any final conclusions can be drawn, further data regarding the outcome of CAP cases that have severe clinical manifestations at presentation and due to macrolide-resistant M. pneumoniae strains are needed.
